EDOXABAN VERSUS WARFARIN IN 841 PATIENTS WITH ATRIAL FIBRILLATION AND PERIPHERAL ARTERIAL DISEASE: INSIGHTS FROM THE ENGAGE AF-TIMI 48 TRIAL